FEATURED NEWS

• HDA Statement on Proposed DEA Rule on Suspicious Orders

  November 2, 2020

  Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., released the following statement regarding the Drug Enforcement Administration’s (DEA) proposed rule on suspicious orders.

• US Biopharmaceutical Supply Chain Resilient and Effective During Early COVID-19 Response

  October 26, 2020

  A report published by the Healthcare Distribution Alliance (HDA) Research Foundation and Deloitte Consulting LLP found that during the first 90 days of the COVID-19 pandemic, the biopharmaceutical finished goods industry quickly adapted and adjusted to deliver medicines safely and efficiently to patients, with only minimal disruptions.

• HDA Statement on FDA’s Drug Supply Chain Security Act-Related Enforcement Discretion

  October 22, 2020

  In response to the Food and Drug Administration’s (FDA) decision to extend enforcement discretion related to certain Drug Supply Chain Security Act requirements, the Healthcare Distribution Alliance (HDA) released the following statement.

• HDA's PCSC Recognizes Supply Chain Security Leaders

  October 8, 2020

  HDA’s Pharmaceutical Cargo Security Coalition recognized three outstanding supply chain security professionals today through the annual PCSC Awards.

• HDA Releases Policy Principles for COVID-19 Vaccine Distribution

  October 8, 2020

  The Healthcare Distribution Alliance (HDA) today released policy principles reaffirming the pharmaceutical distribution industry’s commitment to ensuring — in partnership with federal and state governments — the safe and efficient distribution of COVID-19 vaccines once they are approved by the Food and Drug Administration.